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Background: Refractory status epilepticus (RSE) is a common Neurological Emergency with increased mortality and morbidity in developing countries where facilities of intubation, adequate ventilation, Intensive Care Units (ICUs) and general anaesthesia are not ubiquitously available. Treatment protocols use antiepileptic drugs (AEDs) and need ICU facilities after failure of standard AEDs. Our aim was to see the response to two additional drugs in the armamentarium against refractory status, that is, valproate and levetiracetam. Methods: Patients with generalized RSE admitted in neurology and neurosurgery services at AIIMS during December 2006 to June 2008 were included in the study. The patients were allotted to two groups based on certain criteria. Demographic details, reason for delay, etiology precipitating status, ongoing AEDs therapy, duration of status, the time taken for cessation along with clinical, EEG and MRI correlates were noted. Outcome parameters were analyzed by an independent blinded observer. Results: 82 patients with RSE were studied out of which 41 patients were given IV valproate (Group A) and 41 patients were given IV levetiracetam (Group B). Cessation of status failed in 13 patients in valproate group and 11 patients in levetiracetam group. Majority of the patients did not require ICU settings despite being classified as refractory. Conclusion: RSE can be controlled with intravenous loading and maintenance of valproate or levetiracetam which do not cause respiratory depression, hypotension, need of intubation and ICU care. These must always be considered in a developing country scenario where ICU facilities are not always available or while transporting to centres where these facilities are available. 
Patients and methods
All adults (age > 14 years) with refractory status epilepticus (RSE), which was defined as seizures lasting for more than 60 min (5) and had to have received intravenous lorazepam and phenytoin already. All patients included were admitted in neurology and neurosurgery services (unit 1) at AIIMS over a period of December 2006 to June 2008. The recruitment was done after approval from the Institute Ethics Committee and informed consent was taken. The patients were allotted in two groups. Patients who had no contraindication to valproate and could not afford levetiracetam for continuation therapy were assigned treatment in Group A. Patients who had contraindication to IV valproate or could afford continuation therapy of levetiracetam were assigned Group B. Patients who had contraindications to valproate and could not afford levetiracetam for continuation therapies were excluded from the study. Patients with nonconvulsive and subtle SE, pregnancy, those requiring immediate neurosurgical intervention, patients who had received any or both of the treatments prior to arrival at our Emergency room, patients who were brought intubated or had to be intubated in the Emergency services, were excluded. Demographic and clinical details like gender, age, duration of epilepsy (in years), duration of status epilepticus (in hours), duration of delay in reaching hospital, reasons for delay in reaching the hospital, AED(s) the patient was on, and the etiology of status were noted.
Further, during the hospital stay, the outcome, duration taken for the cessation of status epilepticus, further need for intubation, ICU care and days spent in ICU were also noted.
The valproate group was loaded with 30 mg/kg of intravenous valproate at the rate of 5 mg/kg/min was done. The levetiracetam group received intravenous dose of 30 mg/kg at the rate of 5 mg/ kg/min. Both were generic intravenous preparations. Primary outcome was defined as clinical seizure cessation after infusion and secondary outcome as seizure freedom at 24 h. EEG was performed for a minimum of 1 h, after clinical control of convulsion if the consciousness did not improve however in 22 patients continous EEG could be done for 72 h after clinical cessation of seizures (Nicolet-Viasys).
The evaluator was blinded to the treatment arm the patient was assigned to and the administration was done by senior residents on emergency call on a particular day in the hospital. EEG was read by the evaluator (MT).
Statistical analysis
The data was entered in Microsoft Excel and was analysed by using SPSS version 15 using LEADTOOLS technology. Student t-test was used for comparing continuous variables between the two groups. The qualitative data was analysed by using Pearson chi square/Fischer's exact test wherever applicable. Besides this, the odds ratio and 95% confidence interval were also calculated. Log transformation was also applied to normalize skewed data.
Results
During the study period, 209 patients of RSE were admitted. Of these, 127 patients were excluded (105 patients were either brought intubated or had to be intubated in Emergency services and 23 patients had received any or both of the treatment drugs prior to their arrival in AIIMS). 82 patients with the criteria of refractory generalized status epilepticus were studied in which 41 patients were given IV valproate (Group A) and 41 were given IV levetiracetam (Group B). This was prior to availability of ICU beds (only 5 ICU beds at this centre). Their age ranged from 14 to 35 years. All baseline characteristics were comparable in both groups except for duration of epilepsy which was higher in Group A (Table 1) .
Underlying cause was cryptogenic in 13 patients, neurocysticercosis (NCC) in 9, post-traumatic gliosis in 6, alcohol/metabolic in 5, Mesial Temporal Sclerosis (MTS) in 4, peripartum Cerebral Venous Thrombosis (CVT), stroke and post-encephalitis in 3 each, perinatal insult and cortical dysplasia in 2 each, tuberculoma and Juvenile Myoclonic Epilepsy (JME) in 1 each. There was no difference in the etiology of status in either group (Table 2) .
Reasons for delay to the hospital were lack of knowledge in 30 patients, financial in 9, distance in 8, superstition in 2, and panic in 3. Six patients were not on any AEDs, 13 patients on 1 AED, 15 patients on 2 AEDs, 14 patients on 3 AEDs, and 4 patients on 4 AEDs. 13 patients in Group A and 11 patients in Group B went on to acquire intubation and 2 in each group eventually died. Days of ICU stay in each group were 9 and 7.6 days in Groups A and B respectively (p-value = 0.90) ( Table 3) .
Majority of the patients did not require ICU settings despite being classified as refractory. 13 (31.7%) patients in Group A and 11 (26.8%) patients in Group B could not be controlled and required intubation and administration of propofol or midazolam continuous infusion (p = 0.696). No adverse events like hepatic dysfunction, hypotension, behaviour abnormalities, respiratory depression or thrombocytopenia were reported in any group.
Thus, the efficacy of Group A was 68.3% and of Group B was 73.2% and the difference was not significant. The mean numbers of days spent in hospital were 14.8 days in Group A and 14.33 days in Group B (p = 0.903).
Discussion
Intravenous valproate was first used intravenously in 1978 7 and was administered for SE in 1993 by Giroud et al. 8 Studies in the last decade found it safe as a rapid intravenous infusion for control of status epilepticus. 9, 10 It was only in this decade that a series of studies realized it to be a better choice in patients who had contraindications to phenytoin, were in hypotension. In a country with limited resources it could buy time before the patient can be placed in ICU due to a severe mismatch between resources and the population load. [11] [12] [13] There have been recent trials comparing it to intravenous phenytoin and have found it to be equally safe and have higher efficacy. 14, 15 Intravenous valproate has been incorporated in treatment protocols of treatment of status epilepticus in the recently published studies. 2, 16, 17 Intravenous levetiracetam has been added later in the armamentarium of AEDs which can be used in treatment of status epilepticus. 18 Favourable results have so far been only supplemented by case reports and retrospective case series. 19, [20] [21] [22] [23] [24] Our study is the first, to the best of our knowledge to have prospectively studied the administration of these AEDs before the tertiary drugs for the control of RSE and shown that they can delay and defer the need of intubation and the resultant systemic complications and are without any major side effects in an adult population. This has been done in a very naturalistic setting as treatment trials in status epilepticus are difficult to perform. Hence, the prearranged criteria were used for choosing one drug or the other.
The limitations of our study are that the medication was not masked and the administrators knew what the patient was getting. The sample size is not too large but considering the fact that virtually no home based prehospital treatment by emergency paramedical staff exists in our country any study looking into the treatment prospects of status in a developing country is a drop in the ocean. However our results need confirmation in a larger study.
Conclusion
This study adds the choice of two more good antiepileptic agents in the management of status epilepticus. Both can be used confidently in the same and must be considered while awaiting ICU facilities for status.
